Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Despite tremendous efforts in the search for safe, efficacious and non-addictive opioids for pain treatment, morphine remains the most valuable painkiller in contemporary medicine. Opioids exert their pharmacological actions through three opioid-receptor classes, mu, delta and kappa, whose genes have been cloned. Genetic approaches are now available to delineate the contribution of each receptor in opioid function in vivo. Here we disrupt the mu-opioid-receptor gene in mice by homologous recombination and find that there are no overt behavioural abnormalities or major compensatory changes within the opioid system in these animals. Investigation of the behavioural effects of morphine reveals that a lack of mu receptors abolishes the analgesic effect of morphine, as well as place-preference activity and physical dependence. We observed no behavioural responses related to delta- or kappa-receptor activation with morphine, although these receptors are present and bind opioid ligands. We conclude that the mu-opioid-receptor gene product is the molecular target of morphine in vivo and that it is a mandatory component of the opioid system for morphine action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, in animal models, dopamine D1 receptor knockout rats will not self-administer cocaine37 and μ opioid receptor knockout mice will not show the rewarding effects of opioids.153”
From Neurobiology of addiction: a neurocircuitry analysis (2016) · cites this paper as [153]
In the citing paper
“Mice that lack the MOR gene do not develop place preferences or withdrawal symptoms in response to morphine (Matthes et al 1996).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Matthes et al 1996
Citations
Cites
Kieffer, B. L., Befort, K., Gaveriaux-Ruff, C., & Hirth, C. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12048 · Cited by 1,010
Self-citationNeutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology.
Roques, B. P., Noble, F., Daugé, V, Fournié-Zaluski, M. C., & Beaumont, A. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00449-1 · Cited by 756
Self-citationLufkin, T., Dierich, A., LeMeur, M., Mark, M., & Chambon, P. (1991) · Cell · doi:10.1016/0092-8674(91)90034-v · Cited by 697
Self-citationChiara, G. D., & Alan North, R. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90062-b · Cited by 543
Terwilliger, R. Z., Beitner-Johnson, D., Sevarino, K. A., Crain, S. M., & Nestler, E. J. (1991) · Brain Research · doi:10.1016/0006-8993(91)91111-d · Cited by 535
A brief history of opiates, opioid peptides, and opioid receptors.
Brownstein, M. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5391 · Cited by 491
Multiple opioid receptors: ligand selectivity profiles and binding site signatures.
Goldstein, A., & Naidu, A. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09190-4 · Cited by 445
Kieffer, B. L. (1995) · Cellular and Molecular Neurobiology · doi:10.1007/bf02071128 · Cited by 389
Self-citationReduction of Morphine Abstinence in Mice with a Mutation in the Gene Encoding CREB
Maldonado, R., Blendy, J. A., Tzavara, E., Gass, P., Roques, B. P., Hanoune, J., & Schütz, G. (1996) · Science · doi:10.1126/science.273.5275.657 · Cited by 292
Self-citationThe mouse Pgk-1 gene promoter contains an upstream activator sequence
McBurney, M. W., Sutherland, L. C., Adra, C. N., Leclair, B., Rudnicki, M. A., & Jardine, K. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.20.5755 · Cited by 193
Research works printed but not linked: 9
- Goldstein, A. & Naidu, A. Mol. Pharmacol. 36, 265–272 (1989).
- Pasternak, G. W. Clin. Pharmacol. 16, 1–18 (1993).
- Cowan, A. in Handbook of Experimental Pharmacology Opioids II (ed. Herz, A.) Vol. 104, 393–414 (Springer, Berlin, 1993).
- Roques, B. P., Noble, F., Daugé, V., Fournié-Zaluski, M.-C. & Beaumont, A. Pharmacol. Rev. 45, 87–146 (1993).
- Baamonde, A., Daugé, V., Gacel, C. & Roques, B. P. J. Pharmacol. Exp. Ther. 257, 767–773 (1991).
- Koob, G. F. Trends Biochem. Sci. 13, 177–184 (1992).
- Wei, E. T. J. Pharmacol. Exp. Ther. 216, 12–18 (1981).
- Cowan, A., Zhu, X. Z., Mosberg, H. I., Omnaas, J. R. & Porreca, F. J. Pharmacol. Exp. Ther. 246, 950–955 (1988).
- Kitchen, I. et al. J. Pharmacol. Exp. Ther. 275, 1595–1607 (1995).
Cited by
Items 501–600 of 1,002
Fábián, G., Bozó, B., Szikszay, M., Horváth, G., Coscia, C. J., & Szűcs, M. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.036152 · Cited by 57
“For example, the (cid:1) -opioid receptor is a target of endogenous opioid peptides, synthetic compounds, and morphinan alkaloids (Matthes et al., 1996).”
BackgroundMatsumoto, K., Takayama, H., Narita, M., Nakamura, A., Suzuki, M., Suzuki, T., Murayama, T., Wongseripipatana, S., Misawa, K., Kitajima, M., et al. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.05.003 · Cited by 56
“of hyperlocomotion and place preference in mice (Matthes et al., 1999).”
Ultra-Low Dose Naltrexone Attenuates Chronic Morphine-Induced Gliosis in Rats
Mattioli, T.-A. M., Milne, B., & Cahill, C. M. (2010) · Molecular Pain · doi:10.1186/1744-8069-6-22 · Cited by 56
“Gi protein-coupled μ-opioid receptors [ 3 ,4] located in nociceptive pathways throughout the central nervous system including the dorsal spinal cord.”
BackgroundChu, J., Zheng, H., Loh, H. H., & Law, P. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.05.004 · Cited by 56
Nicotine anxiogenic and rewarding effects are decreased in mice lacking β-endorphin
Trigo, J. M., Zimmer, A., & Maldonado, R. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.03.013 · Cited by 56
“Previous studies have shown a decrease in spontaneous locomotion of KO mice lacking m-opioid receptor (Matthes et al., 1996; Filliol et al., 2000), whereas mice lacking d-opioid receptors exhibited a spontaneous hyperlocomotion (Filliol et al.”
ResultSelf-citationMathon, D. S., Lesscher, H. M. B., Gerrits, M. A. F. M., Kamal, A., Pintar, J. E., Schuller, A. G., Spruijt, B. M., Burbach, J. P. H., Smidt, M. P., van Ree, J. M., et al. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.10.002 · Cited by 63
Vasudevan, L., Vandeputte, M., Deventer, M., Wouters, E., Cannaert, A., & Stove, C. P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113910 · Cited by 55
Region Specific Up-Regulation of Oxytocin Receptors in the Opioid Oprm1−/− Mouse Model of Autism
Gigliucci, V., Leonzino, M., Busnelli, M., Luchetti, A., Palladino, V. S., D’Amato, F. R., & Chini, B. (2014) · Frontiers in Pediatrics · doi:10.3389/fped.2014.00091 · Cited by 56
Morphine Withdrawal Enhances Constitutive μ-Opioid Receptor Activity in the Ventral Tegmental Area
Meye, F. J., van Zessen, R., Smidt, M. P., Adan, R. A. H., & Ramakers, G. M. J. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1572-12.2012 · Cited by 54
Li, Y., Liu, X., Liu, C., Kang, J., Yang, J., Pei, G., & Wu, C. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10030954 · Cited by 55
“Morphine is known to produce analgesia by activating MOR via supraspinal and spinal-related pathways finally located to PAG.”
BackgroundInfluentialMu opioid receptors in pain management
Pasternak, G. W., & Pan, Y. (2011) · Acta anaesthesiologica Taiwanica · doi:10.1016/j.aat.2010.12.008 · Cited by 55
Mu Opioid Pharmacology: 40 Years to the Promised Land
Pasternak, G. W. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.09.006 · Cited by 59
Frantz, M., Pellissier, L. P., Pflimlin, E., Loison, S., Gandía, J., MARSOL, C., Durroux, T., Mouillac, B., Becker, J. A. J., Merrer, J. L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00697 · Cited by 63
Pharmacology of Amphibian Opiate Peptides
Negri, L., Melchiorri, P., & Lattanzi, R. (2000) · Peptides · doi:10.1016/s0196-9781(00)00295-3 · Cited by 55
Sánchez-Cardoso, P., Higuera‐Matas, A., Martı́n, S., Olmo, N. D., Miguéns, M., Garcı́a-Lecumberri, C., & Ambrosio, E. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.011 · Cited by 55
Endomorphins and activation of the hypothalamo-pituitary-adrenal axis
Coventry, T., Jessop, D., Finn, D., Crabb, M., Kinoshita, H., & Harbuz, M. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1690185 · Cited by 55
“Morphine is generally considered as an agonist for the µ-opioid receptor and has been shown to exert its effects via the µ-opioid receptor (Matthes et al. 1996).”
BackgroundNarita, M., Mizoguchi, H., Narita, M., Sora, I., Uhl, G. R., & Tseng, L. F. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702330 · Cited by 55
Quantitative immunolocalization of mu opioid receptors: regulation by naltrexone
Unterwald, E. M., Anton, B., To, T., Lam, H. A., & Evans, C. J. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00659-3 · Cited by 63
Molecular mechanisms of fentanyl mediated β-arrestin biased signaling
de Waal, P. W., Shi, J., You, E., Wang, X., Melcher, K., Jiang, Y., Xu, H. E., & Dickson, B. M. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007394 · Cited by 62
Bailly, J., Rossi, N. D., Runtz, L., Li, J., Park, D., Scherrer, G., Tanti, A., Birling, M., Darcq, E., & Kieffer, B. L. (2020) · eNeuro · doi:10.1523/eneuro.0433-19.2020 · Cited by 55
“…the unrivaled analgesic properties of opioids for pain treatment, and their adverse effects, including notably their strong addictive potential (Matthes et al., 1996; Darcq and Kieffer, 2018), which is driving the current opioid epidemic (World Health Organization, 2017; Volkow and Koroshetz,…”
BackgroundSelf-citationAntón, B., Salazar, A., Zamora, A. F., Matus-Ortega, M., Marín-Navarrete, R., & Hernandez, J.-A. (2009) · Human Vaccines · doi:10.4161/hv.5.4.7556 · Cited by 59
Tracking the opioid receptors on the way of desensitization
Marie, N., Aguila, B., & Allouche, S. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.03.015 · Cited by 55
Wang, Y., Chai, J., Xu, X., Ye, R.-F., Zan, G., Liu, G. Y.-K., Long, J.-D., Ma, Y., Huang, X., Xiao, Z., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-32568-y · Cited by 63
“6, one-way ANOVA assay revealed that the treatments induced significant changes [F(2,27) = 4.”
Araldi, D., Bogen, O., Green, P. G., & Levine, J. D. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.0966-19.2019 · Cited by 54
“MORs are distributed throughout the CNS and within peripheral tissues, neuronal and nonneuronal (Stein et al., 2003; Pathan and Williams, 2012).”
BackgroundInfluentialOlson, K. M., Duron, D. I., Womer, D. E., Fell, R., & Streicher, J. M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217371 · Cited by 60
Angiotensin-converting enzyme gates brain circuit–specific plasticity via an endogenous opioid
Trieu, B. H., Remmers, B. C., Toddes, C., Brandner, D. D., Lefevre, E. M., Kocharian, A., Retzlaff, C. L., Dick, R. M., Mashal, M. A., Gauthier, E. A., et al. (2022) · Science · doi:10.1126/science.abl5130 · Cited by 55
Yamada, H., Shimoyama, N., Sora, I., Uhl, G. R., Fukuda, Y., Moriya, H., & Shimoyama, M. (2006) · Brain Research · doi:10.1016/j.brainres.2006.01.095 · Cited by 54
Lack of dependence and rewarding effects of deltorphin II in mu-opioid receptor-deficient mice
Hutcheson, D. M., Matthes, H. W. D., Valjent, E., Sanchez-Blazquez, P., Rodriguez-Diaz, M., Garzon, J., Kieffer, B. L., & Maldonado, R. (2001) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2001.01363.x · Cited by 54
“MOR-de®cient mice provide a suitable tool for investigating delta and kappa receptor function as the expression of these receptors is not altered in this genotype (Matthes et al., 1996; Kitchen et al., 1997).”
BackgroundMethodInfluentialSelf-citationTranscriptional Regulation of Mouse μ-Opioid Receptor Gene
KO, J. L., Liu, H.-C., Minnerath, S., & Loh, H. H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.42.27678 · Cited by 57
Kest, B., McLemore, G. L., Kao, B., & Inturrisi, C. E. (1997) · PubMed · Cited by 54
Hwang, C. K., Kim, C. S., Kim, D. K., Law, P., Wei, L., & Loh, H. H. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064311 · Cited by 62
Opioid Receptor Interacting Proteins and the Control of Opioid Signaling
Lamberts, J. T., & Traynor, J. R. (2014) · Current Pharmaceutical Design · doi:10.2174/138161281942140105160625 · Cited by 57
“Although all three opioid receptor types are able to modulate nociceptive transmission [16], it is clear that the behavioral effects of morphine are mediated primarily by the μ receptor, as demonstrated by a loss of morphine-mediated analgesia, dependence, and reward in μ receptor knockout mice [17].”
BackgroundLiu, J.-G., Ruckle, M. B., & Prather, P. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106104200 · Cited by 53
Glycogen synthase kinase-3 and p38 MAPK are required for opioid-induced microglia apoptosis
Xie, N., Li, H., Wei, D., LeSage, G., Chen, L., Wang, S., Zhang, Y., Chi, L., Ferslew, K. E., He, L., et al. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.06.006 · Cited by 56
“Introduction Opioids are a standard for treatment of chronic pain, however, their efficacy is limited by side effects including dependence, tolerance, hyperalgesia, mental clouding, and immune modulation (Matthes et al., 1996; Roy et al., 1998).”
BackgroundReduced emotional and corticosterone responses to stress in μ-opioid receptor knockout mice
Ide, S., Sora, I., Ikeda, K., Minami, M., Uhl, G. R., & Ishihara, K. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.07.005 · Cited by 52
“Previous reports using gene mutant mice suggest that MOPs play an important role in various effects of opioids, such as antinociception, tolerance, reward, and locomotion (Ide et al., 2004; Matthes et al., 1996; Sora et al., 2001; Sora et al., 1997).”
BackgroundThe effects of analgesia in the vulnerable infant during the perinatal period
van Lingen, R. A., Simons, S. H. P., Anderson, B. J., & Tibboel, D. (2002) · Clinics in Perinatology · doi:10.1016/s0095-5108(02)00018-0 · Cited by 53
“Transgenic knockout mice have shown that morphine is not analgesic in mice without mu opiate receptors [135–137].”
BackgroundA Computational Model of Craving and Obsession
REDISH, A. D., & JOHNSON, A. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1390.014 · Cited by 52
Potenza, M. N., Gold, S. J., Roby-Shemkovitz, A., Lerner, M. R., & Nestler, E. J. (1999) · PubMed · Cited by 52
Picciotto, M. R. (2010) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-0346-0228-0_14 · Cited by 55
Doyle, G. A. R., Sheng, X. R., Lin, S. S. J., Press, D. M., Grice, D. E., Buono, R. J., Ferraro, T. N., & Berrettini, W. H. (2007) · Gene · doi:10.1016/j.gene.2007.02.004 · Cited by 50
Ostlund, S. B., Kosheleff, A. R., Maidment, N. T., & Murphy, N. P. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3077-x · Cited by 58
“Female wildtype and MOR KO mice, maintained on a C57BL6 background, were derived from an in-house breeding colony produced by heterozygous–heterozygous matings (Matthes et al. 1996).”
MethodGeorgiou, P., Zanos, P., García-Carmona, J. A., Hourani, S. M. O., Kitchen, I., Kieffer, B. L., Laorden, M. L., & Bailey, A. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.09.015 · Cited by 52
Self-citationmiR-365 targets β-arrestin 2 to reverse morphine tolerance in rats
Wang, J., Xu, W., Zhong, T., Song, Z., Zou, Y., Ding, Z., Guo, Q., Dong, X., & Zou, W. (2016) · Scientific Reports · doi:10.1038/srep38285 · Cited by 55
Zhang, X., Dou, Y., Yuan, L., Li, Q., Zhu, Y., Wang, M., & Sun, Y.-G. (2020) · eLife · doi:10.7554/elife.55289 · Cited by 56
“The analgesic effect of morphine-like opioids is mainly mediated by mu-opioid receptor (MOR) (Kieffer, 1999; Matthes et al., 1996), which is encoded by the Oprm1 gene with many splicing isoforms (Chen et al., 1993; Pasternak, 2014; Wang et al., 1993).”
BackgroundStructural Insights Accelerate the Discovery of Opioid Alternatives
Che, T., & Roth, B. L. (2021) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061620-044044 · Cited by 51
Inhibition of morphine tolerance by spinal melanocortin receptor blockade
Starowicz, K., Obara, I., Przewłocki, R., & Przewłocka, B. (2005) · Pain · doi:10.1016/j.pain.2005.07.003 · Cited by 51
μ Opioid receptor: role for the amino terminus as a determinant of ligand binding affinity
Chaturvedi, K., Shahrestanifar, M., & Howells, R. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00332-0 · Cited by 51
Kalange, A. S., Kokare, D. M., Singru, P. S., Upadhya, M. A., Chopde, C. T., & Subhedar, N. K. (2007) · Brain Research · doi:10.1016/j.brainres.2007.08.054 · Cited by 50
Khan, F., & Mehan, A. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.789 · Cited by 53
Synaptic modulation in pain pathways
Zeilhofer, H. U. (2005) · Springer eBooks · doi:10.1007/s10254-005-0043-y · Cited by 59
“…subtypes of opioid receptors has shown that both desired analgesic and unwanted effects of morphine derive from µ-opioid receptor activation (Matthes et al. 1996), disappointing hopes that a separation of desired and unwanted opioid actions could be obtained through selective activation of…”
BackgroundDavid, V., Matifas, A., Gavello-Baudy, S., Decorte, L., Kieffer, B. L., & Cazala, P. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301529 · Cited by 57
“Genetic studies using knockout mice lacking MOR / support this view: morphine-conditioned place preference (CPP) and intravenous morphine self-administration are abolished in MOR / mice (Matthes et al, 1996; Becker et al, 2000; Sora et al, 2001).”
BackgroundMethodResultSelf-citationSrc-family protein tyrosine kinases: A promising target for treating chronic pain
Ge, M.-M., Zhou, Y., Tian, X., Manyande, A., Tian, Y., Ye, D., & Yang, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110017 · Cited by 50
Etorphines: μ-opioid receptor-selective antinociception and low physical dependence capacity
Aceto, M. D. G., Harris, L. S., & Bowman, E. R. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)81924-3 · Cited by 57
Lessov, C. N., & Phillips, T. J. (2003) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2003.tb04398.x · Cited by 59
Zadina, J. E. (2002) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.89.203 · Cited by 50
The IQGAP scaffolds: Critical nodes bridging receptor activation to cellular signaling
Thines, L., Roushar, F. J., Hedman, A. C., & Sacks, D. B. (2023) · The Journal of Cell Biology · doi:10.1083/jcb.202205062 · Cited by 53
Job, M. O., Tang, A., Hall, F. S., Sora, I., Uhl, G. R., Bergeson, S. E., & Gonzales, R. A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.11.016 · Cited by 56
“Because we are the first to report this epistatic interaction between the MOPr and mesolimbic dopamine function, it is not known whether this interaction occurs in MOPr knockout mice generated by other investigators (Loh et al. 1998; Matthes et al. 1996; Schuller et al. 1999; Tian et al. 1997).”
BackgroundMorse, M., Tran, E., Sun, H., Levenson, R. G., & Ye, F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025643 · Cited by 49
“. Knockout mouse studies have shown that the MOR is the opioid receptor subtype primarily responsible for mediating the analgesic and rewarding effects of opioid agonist drugs”
BackgroundLiu, N., von Gizycki, H., & Gintzler, A. R. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.123620 · Cited by 60
“The abolishment by -FNA of i.t. morphine antinociception is consistent with prior reports that the analgesic effects of systemic or i.c.v. administration of morphine are substantially attenuated in MOR knockout animals (Matthes et al., 1996; Sora et al., 1997; Loh et al., 1998).”
III. μ-Opioid receptors in the enteric nervous system
Sternini, C. (2001) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2001.281.1.g8 · Cited by 56
Pharmacogenetics of analgesic drugs
Cregg, R., Russo, G. M., Gubbay, A., Branford, R., & Sato, H. (2013) · British Journal of Pain · doi:10.1177/2049463713507439 · Cited by 57
Involvement of cannabinoid receptors in peripheral and spinal morphine analgesia
Desroches, J., Bouchard, J., Gendron, L., & Beaulieu, P. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.12.030 · Cited by 53
“However, the analgesic effects of morphine were often shown to be completely abolished in MOP KO animals demonstrating that the effects of morphine is mainly mediated by this receptor, at least in vivo (Matthes et al., 1996; Sora et al., 2001; Mizoguchi et al., 2003).”
Ghozland, S. G., CHU, K., Kieffer, B. L., & Roberts, A. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.04.006 · Cited by 51
Self-citationVaughan, C. W., Bagley, E. E., Drew, G. M., Schuller, A. G., Pintar, J. E., Hack, S. P., & Christie, M. J. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705261 · Cited by 52
“…have demonstrated that m-opioid receptors are absent, but the levels of d-, k-opioid and ORL1 receptors are not altered in mice with a m-receptor deletion (Matthes et al., 1996; Kitchen et al., 1997; Sora et al., 1997; Loh et al., 1998; Schuller et al., 1999; Chen et al., 2000; Slowe et al., 2001).”
BackgroundNMDA receptor-dependent long term hyperalgesia after tail amputation in mice
Zhuo, M. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00197-6 · Cited by 52
The Genetics of Addictions: Uncovering the Genes
Goldman, D. A., Oroszi, G., & Ducci, F. (2006) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.4.3.401 · Cited by 57
Silbert, S. C., Beacham, D., & McCleskey, E. W. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00034.2003 · Cited by 48
“Relationship to other studies MOR is the sole receptor responsible for morphine analgesia: it is the only opioid receptor that binds morphine (Goldstein and Naidu, 1989; Raynor et al., 1994); its genetic knock-out eliminates the action of morphine in mice ( Matthes et al., 1996; Sora et al., 1997).”
BackgroundLoss of Morphine Reward and Dependence in Mice Lacking G Protein–Coupled Receptor Kinase 5
Glück, L., Loktev, A., Moulédous, L., Mollereau, C., Law, P., & Schulz, S. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.01.021 · Cited by 55
Glover, E. M., & Davis, M. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1112-0 · Cited by 51
“The pharmacology of morphine and buprenorphine in analgesia, reward, and physical dependence is well characterized, and the μ-opioid receptor has been identified as playing a critical role in these actions (Matthes et al. 1996; Sora et al. 1997).”
BackgroundUpregulation of Nerve Growth Factor in Central Amygdala Increases Sensitivity to Opioid Reward
Bie, B., Wang, Y., Cai, Y.-Q., Zhang, Z., Hou, Y.-Y., & Pan, Z. Z. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.144 · Cited by 47
Doornebal, C. W., Vrijland, K., Hau, C., Coffelt, S. B., Ciampricotti, M., Jonkers, J., de Visser, K. E., & Hollmann, M. W. (2015) · Pain · doi:10.1097/j.pain.0000000000000136 · Cited by 48
“Morphine-induced analgesia was determined using a standardized hot-plate analgesia assay (Columbus Instruments, Columbus, OH) as described by Matthes et al.(31) Briefly, mice were placed on a heated surface (54 ̊C) and paw withdrawal latencies (defined as the time to respond with either a hind paw lick or hind paw fli…”
Method‘Naltrexone Blocks Endorphins Released when Dancing in Synchrony’
Tarr, B., Launay, J., Benson, C., & Dunbar, R. I. M. (2017) · Adaptive Human Behavior and Physiology · doi:10.1007/s40750-017-0067-y · Cited by 48
“It is plausible that certain human group bonding activities activate the EOS, which may play a role in reinforcing the social bonding associated with these activities (Depue and Morrone-Strupinsky 2005; Dunbar 2010; Matthes et al. 1996; Moles et al. 2004).”
BackgroundWu, D.-F., Koch, T., Liang, Y.-J., Stumm, R. K., Schulz, S., Schröder, H., & Höllt, V. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700941200 · Cited by 48
Different affective response to opioid withdrawal in adolescent and adult mice
Hodgson, S. R., Hofford, R. S., Wellman, P. J., & Eitan, S. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.11.002 · Cited by 54
“Additionally, a PubMed search verified that physical dependence on morphine was produced using a similar regimen, namely twice daily injections of escalating morphine doses (el-Kadi and Sharif 1994; Spanagel et al., 1994; Matthes et al., 1996; Kest et al., 2001; Contet et al., 2008).”
BackgroundAzuma, Y., & Ohura, K. (2002) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2002.01128.x · Cited by 51
Gavériaux‐Ruff, C., Filliol, D., Simonin, F., Matthes, H. W. D., & Kieffer, B. L. (2001) · PubMed · Cited by 48
Self-citationAn overview of the genetics of substance use disorders
Lachman, H. M. (2006) · Current Psychiatry Reports · doi:10.1007/s11920-006-0013-3 · Cited by 51
“Knocking out the �-opioid receptor gene, Oprm1, for example, blocks the reinforcing effects of morphine and the drug’s ability to stimulate dopamine release at the NAc [ 19 ].”
BackgroundSingleton, S., Baptista‐Hon, D. T., Edelsten, E., McCaughey, K. S., Camplisson, E., & Hales, T. G. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15409 · Cited by 49
“We similarly assessed TRV130 anti-nociception in μ+/− mice, which express 50% fewer receptors than WT mice (Matthes et al., 1996).”
BackgroundMethodInfluentialMcGovern, D. J., Polter, A. M., Prévost, E. D., Ly, A., McNulty, C. J., Rubinstein, B., & Root, D. H. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01637-w · Cited by 54
Glass, M. J., Lane, D., Colago, E. E. O., Chan, J., Schlussman, S. D., Zhou, Y., Kreek, M. J., & Pickel, V. M. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.01.012 · Cited by 50
“The μ-opioid receptor (μOR) plays an essential role in the rewarding efficacy of morphine, and in the neural and behavioral adaptations associated with chronic opioid exposure, including tolerance and dependence (Chefer et al. 2003; Matthes et al. 1996).”
BackgroundHealy, J., Bezawada, P., Shim, J., Jones, J. W., Kane, M. A., MacKerell, A. D., Coop, A., & Matsumoto, R. R. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn4000428 · Cited by 51
The opioid placebo analgesia is mediated exclusively through µ-opioid receptor in rat
Zhang, R.-R., Zhang, W.-C., Wang, J.-Y., & Guo, J.-Y. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000673 · Cited by 47
Recent Advances in the Realm of Allosteric Modulators for Opioid Receptors for Future Therapeutics
Remesic, M., Hruby, V. J., Porreca, F., & Lee, Y. S. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00090 · Cited by 52
The Life Cycle of the Mu-Opioid Receptor
Cuitavi, J., Hipólito, L., & Canals, M. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.10.002 · Cited by 52
Neve, J. D., Barlow, T. M. A., Tourwé, D., Bihel, F. J. ‐., Simonin, F., & Ballet, S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00041a · Cited by 48
Self-citationKam, A. Y. F., Chan, A. S. L., & Wong, Y. H. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02338.x · Cited by 47
Opioid receptor signaling: relevance for gastrointestinal therapy
Bohn, L., & Raehal, K. M. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.06.007 · Cited by 47
Specific activation of the μ opioid receptor (MOR) by endomorphin 1 and endomorphin 2
Monory, K., Bourin, M., Spetea, M., Tömböly, C., Tóth, G., Matthes, H. W. D., Kieffer, B. L., Hanoune, J., & Borsodi, A. D. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00936.x · Cited by 46
Self-citationThe Downregulation of Opioid Receptors and Neuropathic Pain
Li, L., Chen, J., & Li, Y.-Q. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065981 · Cited by 53
“As the main receptor of the most important analgesic target and related side effects of opioids [14,46,47], MOR remains the center of these studies [48].”
BackgroundDietary Factors Affect Food Reward and Motivation to Eat
Pandit, R., Mercer, J. G., Overduin, J., la Fleur, S. E., & Adan, R. A. H. (2012) · Obesity Facts · doi:10.1159/000338073 · Cited by 46
Wang, Y., & Chan, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-08224-2 · Cited by 50
Hough, L. B., Nalwalk, J. W., Chen, Y., Schuller, A. G., Zhu, Y., Zhang, J., Menge, W. M. P. B., Leurs, R., Timmerman, H., & Pintar, J. E. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02776-1 · Cited by 46
Broadbear, J. H., Sumpter, T. L., Burke, T. F., Husbands, S. M., Lewis, J. W., Woods, J. H., & Traynor, J. R. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39155-4 · Cited by 46
“The role of the m-receptor in opioid pharmacology in the mouse is best studied in knock-out animals (Matthes et al., 1996).”
No heroin or morphine 6β-glucuronide analgesia in μ-opioid receptor knockout mice
Kitanaka, N., Sora, I., Kinsey, S., Zeng, Z., & Uhl, G. R. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00516-0 · Cited by 46
Telomeres and epigenetics: potential relevance to chronic pain
Sibille, K. T., Witek-Janusek, L., Mathews, H. L., & Fillingim, R. B. (2012) · Pain · doi:10.1016/j.pain.2012.06.003 · Cited by 45
“In experimental animals, downregulation of l results in a loss of opiate-induced analgesia and increased sensitivity to pain [22].”
BackgroundTsai, R.-Y., Tai, Y.-H., Tzeng, J. I., Cherng, C., Yeh, C., & Wong, C. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.08.015 · Cited by 49
Let-7 microRNAs and Opioid Tolerance
Hé, Y., & Wang, Z. J. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00110 · Cited by 49
“While MOR is involved in the development of morphine tolerance, it is not the only target for the action of miRs in opioid tolerance (Matthes et al., 1996; Sora et al., 1997).”
BackgroundYekkirala, A. S., Banks, M. L., Lunzer, M. M., Negus, S. S., Rice, K. C., & Portoghese, P. S. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300049m · Cited by 45
Wieskopf, J. S., Pan, Y., Marcovitz, J., Tuttle, A. H., Majumdar, S., Pidakala, J., Pasternak, G. W., & Mogil, J. S. (2014) · Pain · doi:10.1016/j.pain.2014.07.014 · Cited by 49
“Three opioid receptor genes are known, and the vast majority of current opioid analgesics bind to and activate the l-opioid receptor [12], a 7-transmembrane (7-TM) G-protein-coupled receptor.”
BackgroundComparison of opioid receptor distributions in the rat central nervous system
Gray, A. C., Coupar, I. M., & White, P. J. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.02.021 · Cited by 53
Metadata
- Authors
- Matthes, H. W. D., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K., Dierich, A., Le Meur, M., Dollé, P., Tzavara, E., Hanoune, J., Roques, B. P., & Kieffer, B. L.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- University of Surrey (GB)
- Institut de génétique et de biologie moléculaire et cellulaire (FR)
- Inserm (FR)
- Venue
- Nature
- Published
- 1996-10
- Volume
- 383
- Issue
- 6603
- Pages
- 819-823
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2051746492
- Cited by
- 1,722
- References
- 25
- Citations by year
- 2026: 36 · 2025: 40 · 2024: 45 · 2023: 52 · 2022: 53 · 2021: 56 · 2020: 59 · 2019: 56 · 2018: 53 · 2017: 43 · 2016: 59 · 2015: 53 · 2014: 60 · 2013: 65 · 2012: 58
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- mu-opioid receptor, morphine, analgesia, opioid reward, place preference, opioid withdrawal, physical dependence, knockout mice, delta opioid receptor, kappa opioid receptor, opioid system, pain management
- MeSH terms
- Analgesics, Animals, Behavior, Animal, Cell Line, Enkephalins, Mice, Inbred C57BL, Morphine, Morphine Dependence, Narcotics, Reward, Substance Withdrawal Syndrome, Gene Deletion, Receptors, Opioid, mu, Receptors, Opioid, delta, Receptors, Opioid, kappa, Mice, Knockout, Enkephalin, Ala(2)-MePhe(4)-Gly(5)-, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.